AngioDynamics, Inc. $ANGO Shares Bought by Bastion Asset Management Inc.

Bastion Asset Management Inc. lifted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 31.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,264,003 shares of the medical instruments supplier’s stock after acquiring an additional 304,960 shares during the quarter. AngioDynamics makes up 7.7% of Bastion Asset Management Inc.’s portfolio, making the stock its biggest holding. Bastion Asset Management Inc.’s holdings in AngioDynamics were worth $13,442,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. State of Alaska Department of Revenue acquired a new stake in AngioDynamics during the third quarter valued at $25,000. State of Wyoming purchased a new stake in shares of AngioDynamics during the 2nd quarter worth about $31,000. Tower Research Capital LLC TRC lifted its holdings in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 4,268 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $90,000. Finally, Legal & General Group Plc increased its holdings in AngioDynamics by 279.5% in the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 9,098 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Trading Down 0.5%

Shares of AngioDynamics stock opened at $10.97 on Monday. The firm has a fifty day simple moving average of $11.63 and a 200-day simple moving average of $11.23. The stock has a market capitalization of $452.18 million, a price-to-earnings ratio of -16.37 and a beta of 0.52. AngioDynamics, Inc. has a 1-year low of $8.27 and a 1-year high of $13.99.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of analyst reports. Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.